[1] XIAO XH, BAI ZF, WANG JB, et al.Traditional Chinese medicine(TCM) safety evaluation and pharmacovigilance[J]. Chinese Science Bulletin(科学通报), 2021, 66(Z1): 407-414. [2] ZHAO ZH, ZHANG L, LI WB, et al.Research progress on safety evaluation and toxicity of traditional Chinese medicine[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2018, 24(20): 208-216. [3] WANG M, HU WJ, ZHOU X, et al.Ethnopharmacological use, pharmacology, toxicology, phytochemistry, and progress in Chinese crude drug processing of the lateral root of Aconitum carmichaelii Debeaux.(Fuzi): a review[J]. Journal of Ethnopharmacology, 2023, 301: 115838. [4] LUO ZC, ZHANG W, YANG R, et al.Research progress on biopharmaceutical the study of mechanism of Glycyrrhiza uralensis Fisch "moderating property of herbs"[J]. Chinese Traditional and Herbal Drugs(中草药), 2021, 52(1): 267-277. [5] WANG JB, CUI HR, BAI ZF, et al.Precision medicine-oriented safety assessment strategy for traditional Chinese medicines: disease-syndrome-based toxicology[J]. Acta Pharmaceutica Sinica(药学学报), 2016, 51(11): 1681-1688. [6] HOOFNAGLE JH, BJÖRNSSON ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. [7] GAO YJ, ZHAO X, BAI ZF, et al.Prevention and control of safety risks of traditional Chinese medicine based on indirect knowledge of toxicity[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(11): 1004-1008. [8] BAI ZF, WANG JB, XIAO XH.Cognition innovation of toxicity of Chinese medicine and safe and precise medication[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2022, 47(10): 2557-2564. [9] WANG JB, LI CY, ZHU Y, et al.Integrated evidence chain-based identification of Chinese herbal medicine-induced hepatotoxicity and rational usage: exemplification by Polygonum Multiflorum(He shou wu)(in Chinese)[J]. Chin Sci Bull(科学通报), 2016, 61: 971-980. [10] ZHU Y, LIU SH, WANG JB, et al.Clinical analysis of drug-induced liver injury caused by polygonum multiflorum and its preparations B[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2015, 35(12): 1442-1447. [11] TU C, GE FL, GUO YM, et al.Analysis of clinical characteristics and medication rationality of polygonum multiflorum thunb. and its preparation-related liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(5): 270-276. [12] LI C, RAO T, CHEN X, et al.HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357. [13] TU C, NIU M, WEI AW, et al.Susceptibility-related cytokine panel for prediction of polygonum multiflorum-induced hepatotoxicity in humans[J]. J Inflamm Res, 2021, 14: 645-655. [14] ZHANG L, NIU M, WEI AW, et al.Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum[J]. Arch Toxicol, 2020, 94(1): 245-256. [15] BAI ZF, GAO Y, WANG JB, et al.Evaluation and risk control of idiosyncratic liver injury caused by traditional Chinese medicine[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(10): 724-729. [16] BAI ZF, GAO Y, ZUO XB, et al.Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(7): 1019-1026. [17] METUSHI IG, HAYES MA, UETRECHT J.Treatment of PD-1-/-mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients[J]. Hepatology, 2015, 61(4): 1332-1342. [18] MAK A, UETRECHT J.The role of CD8 T cells in amodiaquineinduced liver injury in PD1-/-mice cotreated with antiCTLA-4[J]. Chem Res Toxicol, 2015, 28(8): 1567-1573. [19] CARDONE M, GARCIA K, TILAHUN ME, et al.A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity[J]. J Clin Invest, 2018,128(7): 2819-2832. [20] ONG MM, WANG AS, LEOW KY, et al.Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice[J]. Free Radic Biol Med, 2006, 40(3): 420-429. [21] LEE YH, CHUNG MC, LIN Q, et al.Troglitazoneinduced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury[J]. Toxicol Appl Pharmacol, 2008, 231(1): 43-51. [22] D'UGO E, ARGENTINI C, GIUSEPPETTI R, et al. The woodchuck hepatitis B virus infection model for the evaluation of HBV therapies and vaccine therapies[J]. Expert Opin Drug Discov, 2010, 5(12): 1153-1162. [23] KOSINSKA AD, LIU J, LU M, et al.Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck[J]. Med Microbiol Immunol, 2015, 204(1): 103-114. [24] KNAPP AC, TODESCO L, BEIER K, et al.Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores[J]. J Pharmacol Exp Ter, 2008, 324(2): 568-575. [25] LUYENDYK JP, MADDOX JF, COSMA GN, et al.Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats[J]. J Pharmacol Exp Ther, 2003, 307(1): 9-16. [26] DENG X, STACHLEWITZ RF, LIGUORI MJ, et al.Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation[J]. J Pharmacol Exp Ther, 2007, 319(3): 1191-1199. [27] BUCHWEITZ JP, GANEY PE, BURSIAN SJ, et al.Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?[J]. J Pharmacol Exp Ther, 2002, 300(2): 460-467. [28] SHAW PJ, HOPFENSPERGER MJ, GANEY PE, et al.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factoralpha[J]. Toxicol Sci, 2007, 100(1): 259-266. [29] DUGAN CM, MACDONALD AE, ROTH RA, et al.A mouse model of severe halothane hepatitis based on human risk factors[J]. J Pharmacol Exp Ther, 2010, 333(2): 364-372. [30] SHAW PJ, FULLERTON AM, SCOTT MA, et al.The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability[J]. Toxicol Appl Pharmacol, 2009, 236(3): 293-300. [31] SHAW PJ, GANEY PE, ROTH RA.Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus resulting in neutrophil-dependent liver injury in mice[J]. J Pharmacol Exp Ter, 2009, 330(1) : 2-78. [32] CHENG L, YOU Q, YIN H, et al.Effect of polyI: C cotreatment on halothane-induced liver injury in mice[J]. Hepatology, 2009, 49(1): 215-226. [33] LI CY, LI XF, TU C, et al.The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model[J]. Acta Pharm Sin(药学学报), 2015, 50: 28-33. [34] HE LZ, YIN P, MENG YK, et al.Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu related idiosyncratic liver injury[J]. Sci Bull, 2017, 62(11): 748-751. [35] BAI ZF, HE LZ, MENG YK, et al.Immune idiosyncratic liver injury induced by traditional non-toxic traditional Chinese medicine and a hypothesis of its mechanism[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2017, 52(13): 1105-1109. [36] GAO Y, WANG ZL, TANG JF, et al.New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front Med, 2020, 14(1): 68-80. [37] QIN N, XU G, WANG Y, et al.Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity[J]. Front Med, 2021, 15(4): 594-607. [38] WANG Y, XU G, WANG Z, et al.Psoralidin, a major component of Psoraleae Fructus, induces inflammasome activation and idiosyncratic liver injury[J]. Int Immunopharmacol, 2021, 92: 107352. [39] LIU T, XU G, LI Y, et al.Discovery of bakuchiol as an AIM2 inflammasome activator and cause of hepatotoxicity[J]. J Ethnopharmacol, 2022, 298: 115593. [40] GAO Y, XU G, MA L, et al.Icarisid I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity[J]. Cell Commun Signal, 2021, 19(1): 13. [41] WANG ZL, XU G, WANG HB, et al.Icariside II, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation[J]. Acta Pharm Sin B, 2020, 10(9): 1619-1633. [42] GAO Y, SHI W, TU C, et al.Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim[J]. Front Pharmacol, 2022, 13: 1015846. [43] ZHANG ML, ZHAO X, LI WX, et al.Yin/Yang associated differential responses to Psoralea corylifolia Linn. In rat models: an integrated metabolomics and transcriptomics study[J]. Chin Med, 2023, 18(1): 102. [44] Branch of Chinese Patent Medicine, China Association of Chinese Medicine, Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Committee of Clinical Chinese Pharmacy, Chinese Pharmaceutical Association, et al. Guidelines for safe use of Polygoni Multiflori Radix[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(5): 961-966. [45] WANG YX, LIU B, SHI RB, et al.Research on quality control method of stilbene fraction of Polygonum multifl orum Thunb[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志) , 2009, 24(10): 1277-1280. [46] ZHANG L, BAI ZF, LI CY, et al.Study on idiosyncratic liver injury and content of cis-2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside in radix Polygoni multiflori Preparata[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(7): 1041-1047. [47] SONG D, CHEN SS, LI PY, et al.Attenuating the potential hepatotoxicity of Psoraleae Fructus by pre-processing: the alcohol soaking and water rinsing method[J]. Acta Pharmaceutica Sinica(药学学报), 2020, 55(2): 276-282. [48] SHI W, LIU T, YANG H, et al.Isomaculosidine facilitates NLRP3 inflammasome activation by promoting mitochondrial reactive oxygen species production and causes idiosyncratic liver injury[J]. J Ethnopharmacol, 2024, 319(Pt 1): 117063. [49] WANG Z, XU G, ZHAN X, et al.Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice[J]. Arch Toxicol, 2019, 93(12): 3585-3599. [50] MU W, XU G, WANG Z, et al.Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation[J]. Cell Commun Signal, 2023, 21(1): 123. [51] FU SB, XU G, GAO Y, et al.Inhibitory effect and mechanism of licochalcone A on NLRP3 inflammasome[J]. Acta Pharmaceutica Sinica(药学学报), 2018, 53(12): 2050-2056. [52] LI Q, FENG H, WANG H, et al.Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction[J]. EMBO Rep, 2022, 23(2): e53499. [53] XU G, FU S, ZHAN X, et al.Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90[J]. JCI Insight, 2021, 6(2): e134601. [54] LIU H, ZHAN X, XU G, et al.Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases[J]. Pharmacol Res, 2021, 164: 105384. [55] ZHAO J, LIU H, HONG Z, et al.Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC[J]. Mol Med, 2023, 29(1): 84. [56] SONG HB, SHEN CY.Exploring the safe use and risk management of traditional chinese medicine-a case study of polygonum multiflorum risk management[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2020, 12: 12-18. |